Precision Medicine in Oncology

The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.

Latest News

Advances in Oncology: When Innovation and Challenge Intersect
Advances in Oncology: When Innovation and Challenge Intersect

August 21st 2025

Precision oncology's promise was the key theme of the July 17 session of the Institute for Value-Based Medicine with faculty from multiple institutions in the Boston, Massachusetts area.

There was significant variability in test frequency and detection rates among patients with AML and MDS. | Image credit: Saiful52-stock.adobe.com
Gaps in Molecular Testing Rates, Targeted Treatment Persist in MDS, AML

July 11th 2025

DNA | Image credit: NHS
Breast Cancer and the Use of Predictive Genomics

June 18th 2025

May 2024 News From Strategic Alliance Partners
May 2024 News From Strategic Alliance Partners

May 20th 2024

New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases
New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases

August 16th 2023

More News

Clinical Pathways
December 18th 2020

From Making Oncology Clinical Pathways Multidisciplinary, to Adding the Patient’s Voice

Mary Caffrey
According to the final panel at Patient-Centered Oncology Care®, clinical pathways can create a new problem: if each payer tries to impose its own pathways, it’s an administrative and ethical nightmare.
W. Michael Korn, MD
December 13th 2020

Dr Michael Korn Outlines the Collaborative Nature of the Caris Precision Oncology Alliance

The Caris Precision Oncology Alliance has brought together academic institutions and community practices with the goal of performing research and exchanging evidence and ideas for new types of tests, said W. Michael Korn, MD.
CAR T
December 12th 2020

Creating Personalized Immunotherapy in Large B-Cell Lymphoma

AJMC Staff
The findings help explain why costly CAR T-cell therapy does not work for some patients.
Multiple Myeloma Next Generation Sequencing
December 7th 2020

Clinical Data Show Patient, Cost Benefits of MRD Testing in Multiple Myeloma

Rose McNulty
Data presented at the 62nd Annual ASH Meeting demonstrated the clinical utility of Adaptive Biotechnologies’ clonoSEQ next-generation sequencing to detect MRD in multiple myeloma patients.
Viruses
December 1st 2020

Oncolytic Virus Shows Promise in Colon Cancer Treatment

Rose McNulty
An oncolytic virus called CF33 developed at City of Hope shows potential for colon cancer treatment and tumor regrowth immunity in mouse models.
Pretreating Cells With PAK4 Inhibitor Lets CAR T-Cell Treatment Work in Solid Tumors
November 30th 2020

Pretreating Cells With PAK4 Inhibitor Lets CAR T-Cell Treatment Work in Solid Tumors

Mary Caffrey
Penn Medicine researchers use mice experiments to find a potential solution to the challenge of delivering CAR T cell treatments to solid tumors in glioblastoma.
W. Michael Korn, MD
November 29th 2020

Dr Michael Korn Discusses Precision Medicine Progress in Various Cancers

There are certain diseases, like lung cancer, that are leading the way in precision medicine and where broad molecular testing is recommended, said W. Michael Korn, MD, of University of California, San Francisco, and Caris Life Sciences.
W. Michael Korn, MD
November 23rd 2020

Dr Michael Korn: Access to Precision Oncology Has Improved, but Remains Difficult for Some Populations

In the past, there was a greater discrepancy in access to precision oncology testing, which has closed somewhat; however, there are some disenfranchised populations who still struggle to access this care.
OneOncology and Genentech Partnership Aims to Personalize Community Cancer Care
November 23rd 2020

OneOncology and Genentech Partnership Aims to Personalize Community Cancer Care

Rose McNulty
A first-of-its-kind partnership between OneOncology and Genentech aims to bring more personalized cancer care to community oncology centers nationwide.
Researchers Develop AI Model to Predict ICI Response in Advanced Melanoma
November 20th 2020

Researchers Develop AI Model to Predict ICI Response in Advanced Melanoma

Allison Inserro
Results of the artificial intelligence (AI) model were consistent no matter which immune checkpoint inhibitor (ICI) therapy patients received, suggesting that some biomarkers are not necessarily specific to the checkpoint target.
City of Hope Precision Oncology Tumor Board Identifies Hereditary CRC Risk
November 19th 2020

City of Hope Precision Oncology Tumor Board Identifies Hereditary CRC Risk

Rose McNulty
A precision oncology tumor board at City of Hope identified colorectal cancer patients with possible hereditary predisposition who were not referred for cancer genetics evaluation previously.
Moving Beyond Precision Oncology to “Precision Prevention” in Oncology Practices
November 11th 2020

Moving Beyond Precision Oncology to “Precision Prevention” in Oncology Practices

Christina Mattina
In a pair of sessions at the Quality Cancer Care Alliance Virtual Fall Leadership Summit, speakers discussed the promise of precision medicine for not only informing individuals’ cancer treatment decisions but also identifying individuals at high risk before disease develops.
FDA Approves Liquid CDx for Advanced Castration-Resistant Prostate Cancer
November 10th 2020

FDA Approves Liquid CDx for Advanced Castration-Resistant Prostate Cancer

AJMC Staff
The liquid serum assay was cleared for use as a companion diagnostic for olaparib to identify patients with BRCA1/2- and/or ATM-mutated metastatic castration-resistant prostate cancer.
Study Identifies Molecular Differences Between Pathogenic, Benign Variants
November 7th 2020

Study Identifies Molecular Differences Between Pathogenic, Benign Variants

AJMC Staff
Understanding these genetic variants discovered through sequencing efforts is key to further progress in clinical genetics.
Sibel Blau, MD, Northwest Medical Specialties
November 6th 2020

Dr Sibel Blau Discusses the Importance of Precision Medicine for Cancer Practices

The Quality Cancer Care Alliance is focusing on 2 major topics: value-based care and innovation, and precision oncology is the intersection of those 2 issues, said Sibel Blau, MD.
DNA art
October 30th 2020

Broad Testing for Multiple Genes Benefits Patients With Cancer, Relatives

Allison Inserro
Researchers conducting broad next-generation sequencing discovered more actionable variants in patients and families than they would have otherwise; they did so by using a universal approach, rather than sticking with clinical guidelines.
DNA
October 29th 2020

Foundation Medicine Notches Additional FDA Approvals

AJMC Staff
The FDA has approved new indications for Foundation Medicine's liquid biopsy assay and also its tissue-based companion diagnostic for solid tumors.
Molecules
October 23rd 2020

Cancers of Unknown Primary Site May Benefit From NGS Profiling

Allison Inserro
The study describes how RNA sequencing and DNA sequencing for selected genes were performed simultaneously to evaluate gene expression and alterations in order to predict tumor origin.
OneR
October 19th 2020

OneOncology Launches Research Network Subsidiary

Mary Caffrey
The launch comes as major cancer research organizations are calling for ways to increase diversity in clinical trials.
DNA concept
October 17th 2020

Australian Researchers Illustrate Use of ctDNA in Metastatic Breast Cancer

AJMC Staff
A recent analysis illustrated how a combination of different genomic approaches discovered actionable alterations in 44% of patients with metastatic breast cancer.
Doctor with DNA strands
October 9th 2020

Germline Genetic Testing After Tumor-Only Sequencing Finds Additional Targets, Study Says

Allison Inserro
The researchers, from a medical genetics firm, said the findings illustrate the usefulness of germline analysis for the right patient.
Dr Blythe Adamson: Checkpoint Inhibitor Approval Linked to Uptick in Systemic End-of-Life Care
October 8th 2020

Dr Blythe Adamson: Checkpoint Inhibitor Approval Linked to Uptick in Systemic End-of-Life Care

Blythe Adamson, PhD, MPH, of Flatiron Health, discusses study results she presented at the annual American Society of Clinical Oncology meeting on the use of immune checkpoint inhibitors in end-of-life care
Canadian Study Explores Use of Liquid Biopsies in Advanced NSCLC
October 3rd 2020

Canadian Study Explores Use of Liquid Biopsies in Advanced NSCLC

AJMC Staff
Next-generation sequencing (NGS) of cell-free DNA (cfDNA) may improve diagnostic testing in advanced lung cancer.
Dr. Andre Goy
October 1st 2020

Dr Andre Goy Discusses What We’ve Learned About CAR T Therapies and Cytokine Responses

Andre Goy, MD, of John Theurer Cancer Center, discussed what we’ve learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.
Dr David Debono Previews Precision Health, Value-Based Care Discussion at PCOC® 2020
September 21st 2020

Dr David Debono Previews Precision Health, Value-Based Care Discussion at PCOC® 2020

The opportunity that precision medicine presents in the field of oncology will be further discussed during this year’s Patient-Centered Oncology Care® 2020 virtual meeting.
Olaparib Cuts Risk of Death 31% in BRCA 1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
September 21st 2020

Olaparib Cuts Risk of Death 31% in BRCA 1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

Mary Caffrey
Having biomarker-driven solutions in prostate cancer is important, because they have been lacking.
Osimertinib Sharply Cuts Risk of Brain Metastases After Surgery in EGFR-Mutated NSCLC
September 19th 2020

Osimertinib Sharply Cuts Risk of Brain Metastases After Surgery in EGFR-Mutated NSCLC

Mary Caffrey
A new analysis of ADAURA data shows osimertinib cuts the risk of brain metastases or death by 82% compared with placebo in certain early-stage patients with NSCLC.
Foundation Medicine, Takeda to Work on NSCLC Companion Diagnostics
September 19th 2020

Foundation Medicine, Takeda to Work on NSCLC Companion Diagnostics

AJMC Staff
If approved, FoundationOne's CDx would be used to identify patients with non–small cell lung cancer (NSCLC) who are eligible for mobocertinib or brigatinib.
Study Illustrates Need for Improved Genomic Profiling in Certain Pediatric Cancers
September 18th 2020

Study Illustrates Need for Improved Genomic Profiling in Certain Pediatric Cancers

Jaime Rosenberg
The research spotlights the diverse landscape of pediatric cancer types harboring 2 types of genomic alterations.
FDA Clears Targeted Therapy, Diagnostic for Metastatic RET Fusion-Positive NSCLC
September 9th 2020

FDA Clears Targeted Therapy, Diagnostic for Metastatic RET Fusion-Positive NSCLC

Allison Inserro
Pralsetinib (Gavreto), developed by Blueprint Medicines, received accelerated approval. Thermo Fisher Scientific's Oncomine Dx Target Test received premarket approval as a companion diagnostic to identify patients who are candidates for the once-daily oral RET-targeted therapy.
<123456789
...
14>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo